Breast cancer patients with p53 pro72 homozygous genotype have a poorer survival

Clinical Cancer Research

Volumn 11, Issue 14, 2005, Pages 5098-5103

  Tommiska, Johanna ^a   Eerola, Hannaleena ^a   Heinonen, Mira ^a,b   Salonen, Laura ^a   Kaare, Milja ^a   Tallila, Jonna ^a   Ristimäki, Ari ^a,b   Von Smitten, Karl ^a   Aittomäki, Kristiina ^a   Heikkilä, Päivi ^a   Blomqvist, Carl ^a,c   Nevanlinna, Heli ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; GENE FUNCTION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HISTOPATHOLOGY; HOMOZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 22344450943     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0173     Document Type: Article

References (35)

1. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-100.
2. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004;108:196-9.
3. Dumont P, Leu JI, Delia Pietra AC III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65.
4. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-34.
5. Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet 1999;354:218-9.
6. Zehbe I, Voglino G, Wilander E, et al. p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res 2001;61:608-11.
7. Koushik A, Platt RW, Franco EL. p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev 2004;13: 11-22.
8. Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 2002;179:175-83.
9. Shen H, Solari A, Wang X, et al. P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep 2004;11:1115-20.
10. Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 2002;183:123-30.
11. Granja F, Morari J, Morari EC, Correa LA, Assumpcao LV, Ward LS. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett 2004;210:151-7.
12. Wang YC, Chen CY, Chen SK, Chang YY, Lin P. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 1999;5:129-34.
13. Fan R, Wu MT, Miller D, et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000;9:1037-42.
14. Suzuki K, Matsui H, Ohtake N, et al. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci 2003;10:430-5.
15. Jones JS, Chi X, Gu X, Lynch PM, Amos CI, Frazier ML. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res 2004;10:5845-9.
16. Starinsky S, Figer A, Ben-Asher E, et al. Genotype phenotype correlations in Israeli colorectal cancer patients. Int J Cancer 2004;114:58-73.
17. Papadakis EN, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 2000;3:389-92.
18. Buyru N, Tigli H, Dalay N. P53 codon 72 polymorphism in breast cancer. Oncol Rep 2003;10:711-4.
19. 72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 2003;10: 307-11.
20. Suspitsin EN, Buslov KG, Grigoriev MY, et al. Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer 2003; 103:431-3.
21. Martin AM, Kanetsky PA, Amirimani B, et al. Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1? J Med Genet 2003;40:e34.
22. Syrjakoski K, Vahteristo P, Eerola H, et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 2000;92:1529-31.
23. Kilpivaara O, Bartkova J, Eerola H, et al. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 2005;113:575-80.
24. Eerola H, Blomqvist C, Pukkala E, Pyrhonen S, Nevanlinna H. Familial breast cancer in Southern Finland: how prevalent are breast cancer families and can we trust the family history reported by the patients? Eur J Cancer 2000;36:1143-8.
25. Vehmanen P, Friedman L, Eerola H, et al. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: strong evidence for additional susceptibility genes. Hum Mol Genet 1997;6:2309-15.
26. Vahteristo P, Eerola H, Tamminen A, Blomqvist C, Nevanlinna H. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 2001;84:704-8.
27. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19:403-10.
28. Molland JG, Donnellan M, Janu NC, Carmalt HL, Kennedy CW, Gillett DJ. Infiltrating tabular carcinoma: a comparison of diagnosis, management and outcome with infiltrating duct carcinoma. Breast 2004;13: 389-96.
29. Langerod A, Bukholm IR, Bregard A, et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 2002;11:1684-8.
30. 72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett 2004;210:197-203.
31. Sullivan A, Syed N, Gasco M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004;23:3328-37.
32. Bergamaschi D, Gasco M, Hiller L, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003;3:387-402.
33. Schneider-Stock R, Mawrin C, Motsch C, et al. Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol 2004;164:1233-41.
34. Bonafe M, Ceccarelli C, Farabegoli F, et al. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 2003;9: 4860-4.
35. Goode EL, Dunning AM, Kuschel B, et al. Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res 2002;62: 3052-7.